Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of TQB3616 with Itraconazole and Rifampicin in Healthy Volunteers
NCT06662773Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of culmerciclib in breast cancer and Liposarcoma (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration at 216 hours, Area under drug time curve (AUC0-t) at 216 hours and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancerLiposarcoma
Beyond the preview
Go deeper on NCT06662773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662773.